Fundz

Celosia Therapeutics, a Macquarie University spinout developing gene therapies for motor neurone disease, secured a $2 million grant from NSW government's Emerging Technology Commercialisation Fund.

PRIVATENov 18, 2026

Amount Raised

A$2 Million

Round Type

Grant

New South WalesBiotechnologyHealth CareTherapeutics

Investors

NSW Government

Description

Celosia Therapeutics has been awarded a $2 million grant from the NSW government's new Emerging Technology Commercialisation Fund, the largest grant in the first round of the program. The funding will support expansion of Celosia's MND pipeline, including candidate development, manufacturing work, and preclinical studies for its lead program CTx1000. Celosia will collaborate with the NSW Viral Vector Manufacturing Facility over two years to develop manufacturing processes for a new gene therapy candidate. The biotech, which previously raised $16.75 million in a Series A round in 2024, is developing treatments for motor neurone disease based on research into the TDP-43 protein.

Quick answer

Celosia Therapeutics raised A$2 Million in a Grant round, dated November 18, 2026. Investors: NSW Government. Celosia Therapeutics is based in New South Wales, Australia.

How much did Celosia Therapeutics raise?
Celosia Therapeutics raised A$2 Million in a Grant round on November 18, 2026.
Who invested in Celosia Therapeutics?
NSW Government is named as investors in this round.
What does Celosia Therapeutics do?
Celosia Therapeutics is a Macquarie University spinout developing gene therapies for motor neurone disease (MND), specifically amyotrophic lateral sclerosis (ALS).
Where is Celosia Therapeutics based and how big is it?
Celosia Therapeutics is based in New South Wales, Australia.

Source: Fundz verified event record.

Who else raised in Therapeutics and Biotechnology around the same time

Companies in the same sectors as Celosia Therapeutics that raised within 45 days of this round, from Fundz verified event records.

  • Onward Therapeutics SA raised $28M (Series B) on November 17, 2026.
  • Commit Biologics raised $60M (Seed) on November 17, 2026.
  • 201 Therapeutics raised $178K (Seed) on November 16, 2026.
  • Seawolf Therapeutics raised $100M (Seed) on November 16, 2026.
  • Yicura BioMed raised an undisclosed amount (Series B) on November 13, 2026.
  • Lifeplex Science raised $5.3M (Series A) on November 13, 2026.

Who to call at Celosia Therapeutics, and when

A new round usually means Celosia Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Celosia Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Celosia Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Celosia Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Celosia Therapeutics

Location

New South Wales, Australia

About

Celosia Therapeutics is a Macquarie University spinout developing gene therapies for motor neurone disease (MND), specifically amyotrophic lateral sclerosis (ALS). The company's lead program, CTx1000, is designed to help nerve cells clear toxic protein clumps while preserving healthy proteins needed for cell function. Celosia is currently conducting clinical trials and recently raised $16.75 million in Series A funding.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Celosia Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Celosia Therapeutics's next move

See what Strategic adds

Celosia Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.